bioRxivMicrobiology
Activation of 2,4-diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a putative dioxygenase
Abstract
The diaminoquinazoline series has good potency against Mycobacterium tuberculosis. Resistant isolates have mutations in Rv3161c, a putative dioxygenase. We carried out metabolite analysis on wild-type and an Rv3161c mutant strain after exposure to a diaminoquinazoline. The parental compound was found in intracellular extracts from the mutant, but not the wild-type. A metabolite consistent with a mono-hydroxylated form was identified in the wild-type. These data support the hypothesis that Rv3161c metabolizes diaminoquinazolines in M. tuberculosis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Triazolopyrimidines target aerobic respiration in Mycobacterium tuberculosis
C. D. Shelton, M. B. McNeil, … T. Parish·bioRxiv·Oct 18, 2021
- Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis
J. Xu, P. J. Converse, … E. Nuermberger·bioRxiv·Nov 17, 2020
- Exploiting NDH-2 Vulnerability: Quinolines as Antitubercular Agents
Shashikanta Sau, Rohit Kumar, … Nitin Pal Kalia·bioRxiv·Jun 8, 2026
- In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis
Diana A. Aguilar-Ayala, Marie Sylvianne Rabodoarivelo, … Santiago Ramón‐García·Frontiers in MicrobiologyPeer-reviewed·Jun 29, 2026
- Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines
C. R. M. Asquith, N. Fleck, … W. J. Zuercher·bioRxiv·Jun 18, 2019
- TBI-166 inhibits DlaT and LpdC, exhibiting synergistic effects with Bedaquiline and Pyrazinamide against Mycobacterium tuberculosis
Chennan Liu, L Zhang, … Yu Lu·bioRxiv·May 20, 2026